peter kolchinsky age

Jaimie previously held roles in non-profit and medical settings and worked at Goldman Sachs where she was an Executive Assistant. Kate previously served as Health Law Assistant at Mintz. From time to time we may post specific open positions, but more often we will create positions for the right people. Craig Randall is Assistant General Counsel at RA Capital Management and Counsel at RA Ventures, RA Capital's incubator for new companies. Prior to this role, Anurag was at Orbimed Advisors where he served as Vice President, Structured Growth Capital and Royalty Opportunities. 'All These Sons,' 'Peter Case: A Million Miles Away' Set 2023 Release Jaimie previously held roles as data analyst at Massachusetts Department of Public Health and Anne Arundel Medical Center Department of Medicine. Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. Shan Shans primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Fuad has a BA in Biology with a Minor in Psychology and earned a PhD in Biological Chemistry, both from Washington University in St. Louis. Prior to RA Capital, Tom worked as an Associate at Flagship Pioneering. Prior to RA Capital, Nate worked as an Investment Analyst at Wolfram Ventures. Christy is a Senior Associate with the TechAtlas division of RA Capital Management. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. Previously, Rebecca worked as a Senior Associate within RAs TechAtlas division. Rez holds a BSc in biochemistry and PhD in cell biology from Newcastle University, UK. Drew has a BS in Chemical Engineering from University of Virginia and a PhD in Chemical Engineering from Massachusetts Institute of Technology. Brian Lewandowski is an Analyst on the Investment Team at RA Capital Management. His graduate research investigated the role of fimbria in Bordetella adherence and virulence. Henrys primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. He was also responsible for initiating the transition of the autoimmunity strategy from one based on systemic immunosuppression to a targeted immunomodulation approach. Prior to joining RA, Michael was Associate Vice President at Merck Research Labs. He is co-founder and CEO of Clear Creek Bio, an RA Capital portfolio company. Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). Mariagrace previously worked as an Executive Assistant at MPM Capital. Adison is an Executive Assistant RA Capital Management. Jennas primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Benjamin Hicks is a Venture Operations Associate at RA Capital Management. Joel received his doctorate in Organic Chemistry from Columbia University and his bachelors in Chemistry from the University of Pennsylvania. Prior to RAVen, Natalie served as an EA for three years at Massachusetts Technology Collaborative (MassTech), a Boston agency supporting business formation and growth in the state's technology sector. Erin Clutter is the Head of Graphics at RA Capital Management. Prior to Catamaran, Mark served as Vice President, Legal Affairs at Rubius Therapeutics where he was responsible for leading internal legal activities in support of Rubius IPO and its growth to a clinical-stage company. Fuads primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to that, he held roles as Executive Vice President, Global Head Specialty Medicine and Vice President, Ophthalmology/Global Launch Team Head, EYLEA. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneurs Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Joey holds a Bachelor of Science in Finance from American University and is FINRA-certified in Series 7, Series 63 and Securities Industry Essentials. Andrew Levin is a Partner and Managing Director on the Investment Team at RA Capital Management and spearheads a drug discovery effort that has led to the formation of several new companies. Prior to Blueprint Medicines, he spent two years at Lonza Pharma & Biotech, most recently as Product Development Scientist. Prior to RAVen, he was a member of the founding team and Chief Operating Officer at Catamaran Bio, a CAR-NK cell therapy company. Peter Kolchinsky was born in the United States of America. Habib brings to RAVen nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Her doctoral research focused on bacteriophage-mediated regulation of bacterial transcription. He holds an MD magna cum laude from Harvard-MIT, Program in Health Sciences and Technology, where he was a Paul and Daisy Soros Fellow. Prior to RA, Christy was a Senior Scientist in Oncology Target Discovery at Pfizer. He holds a MS from Northeastern University and a BA from Hamilton College. Her graduate research investigated novel small molecule approaches to treating vestibular schwannoma and neurofibromatosis type 2. Her primary responsibility is leading and executing full cycle recruiting across all newcos and portfolio companies. Alyssa previously worked as a Senior Scientist at Eagle Pharmaceuticals. In this role he works closely with the RA Ventures team to evaluate and incubate early stage therapeutic programs. Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. Let us know if you like it and we may post more pieces with this option.) Josh is a Senior Research Assistant at RA Capital Management. Asthas primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. Mark began his professional career as a life sciences attorney with the law firm of Hale and Dorr (now WilmerHale). Laura has a BS in Chemistry from Yale University and a PhD in Chemical Biology from Harvard University. Peyman Hosseinchi is an Associate within the TechAtlas division of RA Capital Management. Jon's primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Michael received his undergraduate degree at Georgetown University and his medical degree at the Medical University of South Carolina. Prior to RA, Anthony completed the Biopharmaceutical Leadership Development Program at Reata Pharmaceuticals. Previously, Gunes worked closely with the Investment Team, as a Senior Associate within RAs TechAtlas division. Tyler holds a BA in Finance from the University of Massachusetts, Amherst and a certificate in Interactive Design from Rhode Island School of Design. Kaleens primary responsibility is to oversee the initiation, planning, and execution of various projects within the TechAtlas Division. In this role, he gained broad expertise across all phases of drug discovery, early development, and clinical research. Emily Greenis a Visual Identity Designer at RA Capital Management. Most recently, Joe led the administration and support of all Apple products at Curriculum Associates as an IT Systems Engineer. Prior to Point32Health, Michael served as CMO of Harvard Pilgrim Health Care, the Corporate Medical Director at Humana and also served as Vice President of Network and Consumer Solutions for UnitedHealth Groups subsidiary Ingenix (now part of Optum). Age 46 / Jul 1976. Peter Kolchinsky graduated from Harvard with a Ph.D. in virology in 2001. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Hearing the stories of how patients couldn't afford the . Sophie is Chief Medical Officer at Enara Bio, a company focused on novel targets for cancer immune therapy drug discovery. Emily Minkow is a Venture Partner at RA Ventures. David holds a PhD from Harvard University in Biophysics and a BS in Molecular Biology from Texas A&M University. From 2016-2017, Scott served as President of Sojournix, Inc., an asset-focused biopharmaceutical company that he co-founded and served as Board member until 2021. Matt Beverly is a Senior Software Engineer at RA Capital Management. Sarah began her legal career with Foley, Hoag, & Eliot LLP. Patrick joined TRIANA Biomedicines in December of 2021 as President & CEO and Board member after a successful career at Constellation Pharmaceuticals where he served as the companys CSO. Biotech's Dulcius Ex Asperis: The Way Through This Downturn While in these roles, Emily helped Bluebird grow from 300 to 1000 employees. Walter Dauksher is a Junior Associate within the Planetary Health division of RA Capital Management. He worked previously as an Associate Managing Editor at EBSCO Health, and as a Medical Writer at IC Axon and Publicis Life Brands International. Peter Kolchinsky, Ph.D. is a biotechnology investor and a scientist. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. TipRanks & Hedge Funds: TipRanks measures the performance of Peter Kolchinsky and other hedge fund managers based on information submitted to the SEC. His doctoral research focused on breast cancer metastasis. He holds a BA in Environmental Engineering from Dartmouth College (1998), an MA in International Finance and Energy Policy from John Hopkins University (2008), an MS in Materials Science from Columbia University (2012), and a Masters of Strategic Studies from the Army War College (2020). Prior to this, Gerald was Director of Scientific Operations for RA Capital. Alexs primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Before entering the life science space, Kat held various accounting roles in the retail industry and started her career at Ernst & Young. Les primary responsibility is to coordinate various technology related initiatives across the company. The film delves into the psychological roots of Hook's anger, Peter Pan's everlasting childhood, and Wendy's reluctance to face adulthood. Phi's primary responsibilities at RA Capital are to support the Operations team by coordinating calendars, events, and company meetings. Kyle was also the CEO and co-founder of Liquid Light, developer of a proprietary process to make major chemicals from CO2, which was sold to Avantium in 2016. Alex is an Associate with the TechAtlas division of RA Capital Management. Michael is chair of the Board of Managers of the Harvard Pilgrim Health Care Institute. Barrie's classic tale and has a somewhat dark look and feel. Previously, Derek covered solid tumor oncology landscapes. BioVentures. BioSpace's List Of The Top 5 Biggest VC Vampires In Biotech Jessica holds a BA in Linguistics from Brigham Young University and a PhD in auditory neuroscience from the Division of Medical Sciences at Harvard University. Mario is a Venture Partner and Head of Vaccines at RA Capital. Prior to his career at the Broad Institute, Robert was an MIT Leaders for Manufacturing Fellow, and a project manager for Fluor Corporation, where he managed large-scale petrochemical design and construction projects. Prior to this role, Kate worked with the Venture team evaluating early stage investment opportunities and mapped a number of competitive landscapes, including ophthalmology, lower GI, and non-viral liver disease. Megans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Natalie Camacho is an Executive Assistant at RA Ventures (RAVen). I would love to talk to the 1 out of 7 VCs who thinks non-orphan small molecules for older patients are just as investable post Beginning in 2012, and prior to joining the Investment Manager, he was a Vice President at H.I.G. Prior to Akebia, she gained Administrative and Resource Management experience at Wellington Management and Signature Consultants, respectively. Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). At Ra Pharma, Alonso held various leadership roles where he initiated and led the scientific efforts for the company in multiple preclinical and clinical programs; working in a wide set of therapeutic areas and using different molecular modalities. Sarah Reed is the General Counsel at RA Capital Management. Prior to Vor, Sadik served as Executive Director at Kite Pharma and led the development of manufacturing processes for autologous CAR-T and TCR-based cell therapies. He holds a BS in Finance from Providence College. She worked previously in desktop publishing and as a freelance designer. In this role, he will work to evaluate and incubate early-stage therapeutic programs. James holds a BS in Journalism from Boston University and a JD from Boston College Law School. Lucas Guevara is a Compliance Counsel at RA Capital Management. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. GREENWICH Peter Crumbine, a mainstay of public service in Greenwich for decades whose level-headed, friendly and professional manner earned . Previously, was a Research Analyst in the Kauwe lab at Brigham Young University. in Biomedical Anthropology from the University of Pennsylvania. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Priscilla has a B.S. Prior to joining RAVen, Joel was co-founder, President and Chief Scientific Officer at Jnana Therapeutics, a platform company focused on unlocking hard-to-drug targets. Cristina Montero is an Associate Director within the TechAtlas division of RA Capital Management. FORBES estimates that Roivant is worth $3.5 billion, making its Millennial founder's 20% or so stake worth some $700 million. He completed an internship in Internal Medicine and residency in Psychiatry at the University of Utah Health Sciences Center. Patrick was instrumental to building Constellations discovery platform, establishing a portfolio of competitive clinical candidates and drove the maturation of the companys development efforts, leading to one PhIII and two PhII assets and three additional clinical candidates. Andrews primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He worked previously as the Director of Business Systems at Bain Capital Credit, and as a Senior Systems Analyst at eSecLending, LLC. Prior to Indigo, Kathryn was Investment Principal at the Massachusetts Clean Energy Center (MassCEC) where she invested in enterprise and consumer-facing clean energy companies, including software and hardware companies focused on utility and grid resilience, grid edge, next-generation renewables, efficient mobility, industrial efficiency, sustainable buildings, and the water-energy nexus. He holds a Masters degree in Software Engineering from Brandeis University and a BA in Psychology from Providence College. Chris Caliri is the Chief Information Officer at RA Capital Management. Brendan holds a MS in Accounting with a concentration in Taxation from Merrimack College and a BA in Economics from University of Massachusetts Amherst. Prior to joining Aberdeen, Eric worked as a Compliance Examiner at the US Securities and Exchange Commission. In this role, he propelled the company to the next stage of growth and increased shareholder value by altering the course of this formerly research-based company to prioritize innovation, speed to commercialization, and culture transformation. Pieters primary responsibility at RA Capital is to lead major strategic initiatives and drive operational excellence across the firm. Shannon's primary responsibilities are to manage the front desk and office facilities. Prior to joining RA, Kyle was a Partner at Breakthrough Energy Ventures (BEV), where he led investments and served on company boards that span the utilities, energy storage, chemicals, agriculture, automotive, recycling, and consumer products sectors. Erins primary responsibilities at RA Capital are to manage the design and creation of all internal and external documents and resources for the company, including competitive landscapes of drugs and medical devices for disease indications and capabilities, set brand standards, and oversee internal and external marketing efforts. The Great American Drug Deal | Peter Kolchinsky, PhD - NetGalley Jake Simson is a Partner at RA Capital Management. Mario received postdoctoral training at the NIH and Mount Sinai School of Medicine in innate immunity and bioinformatics, earned a PhD in microbiology at University of Chile and a MS in Nuclear Physics. Max DeNies is a Senior Associate with the TechAtlas division of RA Capital Management. Gunes holds a BSc in Biological Sciences and Bioengineering from Sabanci University, a MSc in Molecular and Cellular Biology and a PhD in Biochemistry from the University of Heidelberg.
Trailers For Rent Calhoun, Ga, Bax And O'brien Leave Of Absence, Articles P